Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Evaxion significantly expands vaccine development collaboration with MSD
Friday, September 27, 2024Evaxion Biotech AS a clinicalstage TechBio company specializing in developing AIImmunology powered vaccines today announced that it has entered into an option and license agreement with MSD tradename of Merck Co Inc Rahway NJ USA for two preclinical...
Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease
Friday, September 27, 2024Acumen Pharmaceuticals Inc a clinicalstage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta A oligomers AOs for the treatment of Alzheimers disease AD announced today that it has extended its collaborat...
BlueRock Therapeutics’ investigational cell therapy bemdaneprocel for Parkinson’s disease shows positive data at 24-months
Friday, September 27, 2024Bayer AG and BlueRock Therapeutics LP a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG today announced positive month data from exPDite a Phase clinical trial of bemdaneprocel an investigational ce...
PolTREG starts preclinical CAR-Treg development for neuroinflammatory autoimmune diseases
Thursday, September 26, 2024PolTREG SA a clinicalstage biotechnology company developing cellular therapies for a range of autoimmune diseases today announces it has launched a study with CARTreg cells in a humanized mouse model of neuroinflammatory disease Data from the study a...
Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)
Thursday, September 26, 2024Pharming Group NV announces that the United Kingdom UK Medicines and Healthcare products Regulatory Agency MHRA has granted marketing authorization for Joenja leniolisib for the treatment of activated phosphoinositide kinase delta
Quell Therapeutics Expands Manufacturing Capabilities for CAR-Treg Cell Therapy Pipeline Through Partnership with eXmoor pharma
Wednesday, September 25, 2024Quell Therapeutics Ltd a world leader in developing engineered Tregulatory Treg cell therapies for serious medical conditions driven by the immune system and eXmoor pharma eXmoor the fullservice cell and gene therapy CGT manufacturing partner
Bavarian Nordic Awarded USD 63 Million from the U.S. Government for Production and Supply of Additional Smallpox/Mpox Vaccines
Wednesday, September 25, 2024Bavarian Nordic AS announced that it has received an additional order valued at USD million from the Biomedical Advanced Research and Development Authority BARDA part of the Administration for Strategic Preparedness and Response
Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses
Tuesday, September 24, 2024Roche announced today the launch of the cobas Respiratory flex test the first to use Roches novel and proprietary TAGS TemperatureActivated Generation of Signal technology TAGS technology developed by Roche scientists uses multiplex
SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment
Tuesday, September 24, 2024SciSparc Ltd a specialty clinicalstage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system today announced that the US Food and Drug Administration FDA has confirmed
TCBP Announces First Patient Completed the Full Dose Regimen in ACHIEVE Clinical Trial
Monday, September 23, 2024TC BioPharm Holdings PLC a clinical stage biotechnology company developing platform allogeneic gammadelta T cell therapies for cancer and other indications today announces the first patient has completed the full dose regimen in the ACHIEVE Phase
